To include your compound in the COVID-19 Resource Center, submit it here.

Ipsen discontinues Irosustat monotherapy

Ipsen Group (Euronext:IPN) discontinued development of Irosustat as a monotherapy after a

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE